A neural signature to predict attention shifting delays in children and adults

Nature Neuroscience, Published online: 08 June 2026; doi:10.1038/s41593-026-02295-z

Moment-to-moment lapses in attention shifting impair behavior and learning. These lapses are common in individuals with neurodevelopmental disorders involving attention deficits. We identify a neural signature that predicts delayed performance on a set-shifting task and show that real-time closed-loop neuromodulation can prevent lapses and improve performance.

Cortical On/Off Switch Provides Sleep Benefits to Awake Mice

Researchers have demonstrated that key restorative functions of sleep can be triggered in localized regions of the awake brain, providing new insights into why sleep is essential for learning and memory.

The NIH-funded study, led by investigators at the University of Wisconsin–Madison, showed that artificially inducing sleep-like patterns of neural activity in specific brain regions of sleep-deprived mice restored memory performance and reduced the need for subsequent sleep in those areas. The findings, published in Nature Neuroscience, suggest that the characteristic activity patterns of non-rapid eye movement (NREM) sleep, not simply reduced brain activity, play a central role in maintaining healthy neural circuits.

The work offers a new window into the biological mechanisms that allow sleep to refresh the brain and may eventually inform non-invasive approaches to combat cognitive impairment associated with sleep loss.

A closer look at sleep’s restorative role

Researchers have long shown that sleep is essential for memory formation and learning, but the precise mechanisms underlying these benefits remain incompletely understood.

During NREM sleep, which accounts for approximately 80% of adult sleep, the brain undergoes extensive reorganization. Connections between neurons, known as synapses, are selectively strengthened, maintained, or weakened. This process is thought to secure important memories while preventing neural networks from becoming overloaded with information accumulated during wakefulness.

Previous studies from the laboratory of senior author Chiara Cirelli, MD, PhD, found that sleep-deprived animals and humans occasionally exhibit brief episodes of localized slow-wave activity, the characteristic electrical pattern of NREM sleep, even while remaining awake. These observations raised the possibility that small portions of the brain might temporarily enter a sleep-like state independently of the rest of the brain.

The question remained whether a more sustained version of this phenomenon could reproduce some of sleep’s restorative effects.

Inducing local sleep while animals remain awake

To investigate, the researchers developed an experimental system that allowed them to generate sleep-like activity in targeted regions of the brain without causing the animals to fall asleep.

Using genetically modified mice equipped with light-sensitive neural circuits, the team delivered rhythmic pulses of light that produced alternating periods of neuronal activation and silence. These oscillations closely resembled the “on-off” firing patterns observed during NREM sleep.

The stimulation was applied to one hemisphere of the brain in sleep-deprived mice for 30-minute periods while the animals remained awake and responsive to their environment.

Cirelli compared the phenomenon to a strategy observed in nature.

“What we’re essentially doing is forcing sleep in a local region of the brain,” she said. “While that part is solidifying memories and restoring learning capacity, other parts stay aware/vigilant and connected to environment.”

She noted that dolphins exhibit a related behavior, sleeping with one cerebral hemisphere at a time while the other remains awake.

Reduced need for recovery sleep

The researchers found that brain regions receiving the sleep-like stimulation subsequently displayed lower levels of slow-wave activity during natural sleep.

Slow-wave activity is widely considered a measure of sleep pressure, the biological drive to sleep that accumulates during wakefulness. Reduced slow-wave activity suggested that the stimulated brain regions had already undergone part of the restorative process normally achieved during sleep.

The results challenged a longstanding hypothesis that sleep’s benefits primarily arise from globally reducing neuronal firing rates to relieve fatigue.

Instead, the study found that restoration depended specifically on the rhythmic alternation between active and inactive states characteristic of NREM sleep. Simply suppressing neuronal activity was insufficient.

The findings suggest that the temporal structure of neural activity during sleep may be more important than the overall amount of activity.

Restoring memory after sleep deprivation

To determine whether the induced sleep-like activity produced meaningful behavioral benefits, the researchers evaluated the animals using a tactile memory task that normally depends on adequate sleep.

Sleep-deprived mice typically perform poorly on this type of test, reflecting impaired memory consolidation and reduced learning capacity.

However, sleep-deprived mice that received bilateral stimulation of sensory and motor brain regions performed nearly as well as animals that had not been deprived of sleep. In contrast, sleep-deprived mice that did not receive stimulation showed significantly impaired performance.

These results suggest that localized sleep-like activity can compensate for at least some of the cognitive deficits caused by sleep loss.

Understanding how the brain resets

The work provides new support for the concept that sleep serves as a form of neural recalibration.

Throughout wakefulness, experiences continuously modify synaptic connections, increasing the strength and number of neural links. Without a mechanism to rebalance these networks, the brain could eventually lose efficiency, consume excessive energy, and struggle to encode new information.

NREM sleep appears to provide a structured period during which these connections are selectively refined. The current study indicates that the characteristic slow oscillations of NREM sleep may be the critical driver of this process.

By recreating these oscillations in isolated brain regions, researchers were able to trigger aspects of the reset mechanism without requiring the entire brain to enter sleep.

Potential implications for human health

Although the experiments relied on invasive genetic and optical techniques that are not currently applicable to humans, the investigators believe the findings may inform future therapeutic strategies.

The next step will be determining whether similar effects can be achieved using non-invasive approaches such as transcranial brain stimulation, which can modulate neural activity through the scalp.

If successful, such methods could eventually help mitigate cognitive deficits associated with sleep deprivation, shift work, aging, or neurological disorders.

“This research further decodes why we sleep and how we learn, which brings us a step closer to understanding how to better prevent and treat cognitive decline,” said Amy Bany Adams, PhD, acting director of the NIH’s National Institute of Neurological Disorders and Stroke.

While a replacement for sleep remains firmly out of reach, the study reveals that some of sleep’s most important restorative processes may be far more localized, and potentially more controllable, than previously appreciated.

The post Cortical On/Off Switch Provides Sleep Benefits to Awake Mice appeared first on Inside Precision Medicine.

GLP-1 Drugs Linked to Lower Rates of Substance Use Disorders

A study led by researchers at the University of Texas at El Paso (UTEP) has found that people with type 2 diabetes or obesity who were prescribed GLP-1 receptor agonists (GLP-1 RAs) had substantially lower odds of developing alcohol, opioid, nicotine, and cocaine use disorders compared with similar individuals who were not taking the medications. The research, published in the journal Frontiers in Psychiatry, used health data from more than 142,000 patients from the All of Us Research Program and adds to a growing body of evidence indicating that GLP-1 medications may have an influence on dopamine signaling and other neural pathways that drive cravings not just for food but other substances.

“Our findings add to growing evidence that GLP-1 medications may influence more than appetite and blood sugar regulation,” said lead author Tadesse Abegaz, PhD, an assistant professor in the School of Pharmacy, University of Texas at El Paso. “These medications appear to affect brain pathways involved in reward and craving, which could help explain the lower rates of substance use disorders observed in our study.”

Substance use disorders are a significant public health challenge contributing to illness, premature death, and higher healthcare costs. While current treatment methods that combine medications and behavioral therapy can be effective, relapse rates remain high, often exceeding 50% within the first year after treatment, suggesting a need for additional ways to treat this disease.

An emerging candidate for this are GLP-1 receptor agonists such as semaglutide and liraglutide. Developed to treat type 2 diabetes and obesity, these drugs have drawn attention because GLP-1 receptors are found not only in areas involved in metabolic regulation but also in brain regions associated with reward and reinforcement.

“Animal studies have demonstrated that GLP-1 RAs reduce the self-administration of alcohol, opioid, nicotine, and cocaine effects [that] are believed to be mediated through interactions with the mesolimbic dopamine system,” the researchers wrote. Small human studies and observational analyses have also suggested reductions in substance cravings, relapse rates, and alcohol-related hospitalizations among some patients receiving GLP-1 therapies.

The El Paso investigators said they initiated their research to move beyond smaller studies because “the real-world impact of GLP-1 RA on multiple co-occurrence of SUD (substance use disorder) has not been systematically investigated.”

To address this gap, the team conducted a retrospective nested case-control study using data from the NIH’s All of Us Research Program. The study examined individuals with type 2 diabetes or obesity and identified cases involving new diagnoses of alcohol use disorder, opioid use disorder, nicotine use disorder, or cocaine use disorder. These individuals were compared with matched control participants who had diabetes or obesity but no documented history of substance use disorders.

Analyses of these data showed consistent associations across all categories studied. GLP-1 receptor agonist use was associated with a 74% reduction in the odds of alcohol use disorder, a 69% reduction in the odds of opioid use disorder, a 68% reduction in the odds of nicotine use disorder, and a 75% reduction in the odds of cocaine use disorder. The researchers also reported 75% lower odds of any substance use disorder among GLP-1 users compared with non-users.

“Exposure to GLP-1 RAs was consistently associated with significantly reduced odds of SUD cases,” the researchers wrote. “These findings suggest that GLP-1 RAs may exert behavioral-modifying effects that extend beyond glycemic control and weight loss.”

The researchers noted that their research was observational and does not establish cause and effect. “We do not support prescribing these medications for addiction treatment at this time,” said senior author Gabriel Frietze, PhD, an assistant professor of pharmaceutical sciences at UTEP. “Because this was an observational study in a specific clinical population, randomized clinical trials are needed before GLP-1 medications can be recommended for treating addiction.”

The team believes the findings could help guide future approaches to addressing substance use-related health issues by identifying biological pathways that may be targeted therapeutically. The authors noted that mechanisms potentially involved include modulation of dopamine release, suppression of neuroinflammation, and attenuation of stress-related neural circuits.

“Our next goal is to conduct prospective research that follows individuals initiating GLP-1 therapy over time,” Abegaz said. “We aim to evaluate whether changes in the substance use behaviors occur after treatment begins and whether these changes related to improvements in mental health and quality of life. Ultimately, this work will help inform whether GLP-1 medications could become part of future treatment strategies for substance use disorders.”

The post GLP-1 Drugs Linked to Lower Rates of Substance Use Disorders appeared first on Inside Precision Medicine.

Postnatal maternal mental health-related hospitalisation and its association with adverse child health and maltreatment outcomes: narrative review

BackgroundMaternal mental health conditions within the postnatal period can have long-lasting consequences on a child’s well-being. This study synthesises current evidence on the association between postnatal maternal mental health-related hospitalisation (MHrH) and adverse child health and maltreatment outcomes.MethodsWe conducted an inclusive search across multiple databases, including MEDLINE, PsycINFO, CINAHL, Scopus, Embase, Google Scholar, and the reference list of eligible papers. Studies that used standardised outcome measures were included. Study selection and data extraction were made using a standardised Joanna Briggs Institute (JBI) tool. The quality of the studies was assessed using the Newcastle-Ottawa Scale (NOS). Descriptive vote counting to map the direction of effects, alongside narrative thematic synthesis, was used to summarise the findings from the included studies.ResultsFour studies (n = 1,020,342) were included in the review. Three of these studies suggest a possible association between postnatal maternal MHrH and adverse child health outcomes (growth failure, respiratory and gastrointestinal infection) or maltreatment (sexual, physical, and emotional abuse). One study did not find a statistically significant association between postnatal maternal MHrH and infant growth.ConclusionThe available evidence suggests a possible association between postnatal maternal MHrH and adverse child health and maltreatment outcomes. However, given the small number of studies and methodological heterogeneity, these findings should be interpreted cautiously and highlight the need for further high-quality longitudinal research.Systematic Review Registrationhttps://www.crd.york.ac.uk/prospero/, identifier CRD42023446155.

Integrative mechanisms and intervention targets of the microbiota–gut–brain axis in depressive disorders: advances across immune, endocrine, and central nervous system pathways

Depressive disorders are highly heterogeneous syndromes characterized not only by depressed mood but also by cognitive impairment, sleep–circadian rhythm disturbances, altered appetite, somatic discomfort, and metabolic or gastrointestinal comorbidities. In recent years, the microbiota–gut–brain axis (MGBA) has been increasingly recognized as an integrative biological framework linking abnormalities in mood regulation, immune responses, endocrine function, metabolism, and neuroplasticity. This review provides a systematic synthesis of gut microbial ecology and host phenotypic features associated with depressive disorders, with particular emphasis on the depletion of short-chain fatty acid-producing commensals, the enrichment of potentially pro-inflammatory taxa, and the functional remodeling of key metabolic pathways, including the tryptophan–kynurenine pathway, short-chain fatty acids, bile acids, and trimethylamine N-oxide. We further discuss how bidirectional gut-to-brain and brain-to-gut communication may contribute to the onset and progression of depressive disorders through intestinal barrier disruption, low-grade systemic inflammation, hypothalamic–pituitary–adrenal axis activation, vagal signaling, and dysregulation of neurotransmitter and neurotrophic pathways. Current interventional evidence suggests that dietary and lifestyle modification, psychobiotics, and fecal microbiota transplantation may exert antidepressant potential in selected populations; however, the overall effect sizes remain limited and between-study heterogeneity is substantial. Patients with prominent gastrointestinal symptoms, metabolic abnormalities, or low-grade inflammatory states may represent priority candidates for MGBA-targeted interventions; nevertheless, a putative microbiota-responsive phenotype should not be simply equated with high stress exposure alone, and its definition requires prospective validation integrating stress burden, host responses, and microbial/metabolic readouts. Overall, MGBA research is gradually moving beyond descriptive profiling of microbial composition toward functional integration and clinical translation; however, causal inference, multi-omics standardization, and the identification of stratification biomarkers remain major challenges. Future studies should incorporate phenotype-based stratification, strengthened functional readouts, and precision intervention designs to determine which patients are most likely to benefit from microbiota-targeted therapies.

Evaluating an Abbreviated Internet-Delivered Stress Recovery Intervention for Health Care Workers: Pre-Post Feasibility Study of Outcomes, Usability, and Acceptability

<strong>Background:</strong> Health care workers face numerous occupational stressors that place them at heightened risk for burnout and poor mental health. Internet-delivered interventions have shown promise in reducing stress and related symptoms, yet adherence is often low, and users do not complete programs. Abbreviated interventions may help address engagement barriers such as high workload, limited time, and varying user preferences. There is a need to evaluate brief, accessible formats of internet-delivered programs for this population. <strong>Objective:</strong> This study aimed to examine the initial outcomes, usability, and acceptability of a 4-week abbreviated internet-delivered stress recovery intervention for health care workers. Specifically, it evaluated changes in stress recovery, perceived stress, depression and anxiety symptoms, and psychological well-being. The study also sought to understand participants’ experiences with the brief format to determine whether it meets their needs. <strong>Methods:</strong> This single-arm pre-post study examined a 4-week abbreviated version of the online guided cognitive behavioral therapy-based stress recovery program FOREST among self-enrolled health care workers recruited through professional networks (N=52; mean age 39.31, SD 11.31 years; 49/52, 94.2% women). Outcomes included stress recovery (the Recovery Experience Questionnaire), perceived stress (the Perceived Stress Scale-4), depression and anxiety symptoms (the Patient Health Questionnaire-4), psychological well-being (the World Health Organization Well-being Index), and usability and acceptability ratings. <strong>Results:</strong> We found that after the abbreviated version of the FOREST intervention participants showed moderate improvements in stress recovery (<i>d</i>=0.54, 95% CI 0.25-0.83); reductions in stress (<i>d</i>=–0.43, 95% CI –0.72 to –0.14), anxiety and depression symptoms (<i>d</i>=–0.51, 95% CI –0.80 to –0.22); and increase in psychological well-being (<i>d</i>=0.39, 95% CI 0.08-0.70). The majority (37/52, 71.2%) accessed all 6 modules. Users reported high satisfaction with the abbreviated program. <strong>Conclusions:</strong> While preliminary and limited by the pre-post design, these findings indicate that abbreviated internet-based stress recovery programs are a promising and practical tool for supporting the mental health of health care workers. Future research should examine the long-term effects, compare the abbreviated and standard versions, and explore implementation in routine practice. <strong>Trial Registration:</strong>